Recently, the role of the VHL-HIF pathway in RCC has been emphasized, and HIF-2α inhibitors have also become a treatment option for patients with metastatic RCC (Roviello et al., 2024). This evidence concerns the gene VHL and renal cell adenocarcinoma.